DENOSUMAB VERSUS ZOLEDRONIC ACID FOR PREVENTING SKELETAL-RELATED EVENTS IN PATIENTS WITH METASTATIC BONE DISEASE: SUBGROUP ANALYSES BY BASELINE CHARACTERISTICS

被引：0
|
作者：
Stopeck, A. [1 ]
Lipton, A. [2 ]
Fizazi, K. [3 ]
Smith, M. R. [4 ,5 ]
Shore, N. D. [6 ]
Martin, M. [7 ]
Vadhan-Raj, S. [8 ]
Zhou, K. [9 ]
Balakumaran, A. [9 ]
Braun, A. H. [9 ]
机构：
[1] Univ Arizona, Ctr Canc, Tucson, AZ USA
[2] Penn State Hershey Med Ctr, Hershey, PA USA
[3] Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[4] Massachusetts Gen Hosp, Ctr Canc, Dept Hematol, Boston, MA USA
[5] Massachusetts Gen Hosp, Ctr Canc, Dept Oncol, Boston, MA USA
[6] Atlantic Urol Clin, Carolina Urol Res Ctr, Myrtle Beach, SC USA
[7] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[8] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Sect Cytokines & Support Oncol, Houston, TX 77030 USA
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [21] Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer
    Irelli, Azzurra
    Cocciolone, Valentina
    Cannita, Katia
    Zugaro, Luigi
    Di Staso, Mario
    Baldi, Paola Lanfiuti
    Paradisi, Stefania
    Sidoni, Tina
    Ricevuto, Enrico
    Ficorella, Corrado
    BONE, 2016, 87 : 169 - 175
  • [22] Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC).
    Snedecor, S. J.
    Carter, J. A.
    Kaura, S.
    Botteman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Skeletal-related events in patients with solid tumors receiving denosumab or zoledronic acid by baseline pain status: Results from three phase 3 trials
    Von Moos, R.
    Stopeck, A.
    Fizazi, K.
    Cleeland, C.
    Brown, J. E.
    Oudard, S.
    Costa, L.
    Wang, H.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S268 - S268
  • [24] Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid
    Major, PP
    Cook, RJ
    Chen, BL
    Zheng, M
    BONE, 2004, 34 : S88 - S88
  • [25] Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: A comparison with skeletal-related events (SREs)
    Body, J-J.
    von Moos, R.
    Lipton, A.
    Martin, M.
    Diel, I.
    Steger, G.
    Tonkin, K.
    de Boer, R.
    Radcliffe, H-S.
    Niepel, D.
    Stopeck, A. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] Symptomatic skeletal events (SSEs) versus skeletal- related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid
    von Moos, R.
    Costa, L. A. M.
    Scagliotti, G.
    Sleeboom, H.
    Goldwasser, F.
    Hirsh, V.
    Spencer, A.
    Radcliffe, H-S.
    Niepel, D.
    Henry, D. H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] COST-EFFECTIVENESS OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR SKELETAL-RELATED EVENT (SRE) REDUCTION IN BONE-METASTATIC PROSTATE CANCER (MPC) IN THE UK
    Botteman, M. F.
    Carter, J. A.
    Fishman, P.
    Chandiwana, D.
    Bains, M.
    Snedecor, S. J.
    VALUE IN HEALTH, 2012, 15 (07) : A420 - A421
  • [28] Multidisciplinary approach for preventing skeletal-related events in patients with bone metastasis
    Ito, Shigeki
    Suzuki, Tomohiro
    Ariga, Hisanori
    Murakami, Hideki
    Kimura, Yusuke
    Endo, Hirooki
    Nakayama, Manabu
    Ishida, Kazuyuki
    Sugai, Tamotsu
    Ehara, Shigeru
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid - Combined Analysis From 3 Registrational Trials
    Lipton, A.
    Fizazi, K.
    Stopeck, A. T.
    Henry, D. H.
    Brown, J. E.
    Saad, F.
    Yardley, D.
    Maroto, P.
    Ke, C.
    Jun, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S240 - S240
  • [30] Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer
    Carter, John A.
    Botteman, Marc F.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (04) : 425 - 437
12345